Research analysts at StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a report released on Thursday. The firm set a “sell” rating on the stock. Separately, Mizuho reissued a “neutral” rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research report on Thursday, March 30th. […]
StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research note issued to investors on Tuesday morning. The firm issued a sell rating on the stock. Separately, Mizuho restated a neutral rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research note on Thursday, March […]
StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a report released on Monday. The brokerage issued a sell rating on the stock. Separately, Mizuho reissued a neutral rating and set a $3.50 price objective on shares of Corvus Pharmaceuticals in a report on Thursday, March 30th. Corvus Pharmaceuticals Stock Performance […]
Mizuho restated their neutral rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research report sent to investors on Thursday, Benzinga reports. The firm currently has a $3.50 target price on the stock. Separately, StockNews.com began coverage on Corvus Pharmaceuticals in a research report on Sunday, March 26th. They issued a sell […]
StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a report published on Sunday. The firm issued a sell rating on the stock. Corvus Pharmaceuticals Stock Up 11.3 % Shares of Corvus Pharmaceuticals stock opened at $0.72 on Friday. The company has a market capitalization of $33.59 million, a price-to-earnings ratio […]